SHF Holdings, Inc. (SHFS) · Oct 26, 2026 · Acquisition
85% Opifex ownership — Opifex holders 85%; existing SHF stakeholders 15% fully diluted
SHF Holdings announced a non-binding acquisition term sheet that would give Opifex 85% of the combined company while preserving SHF’s listing.
Safe Harbor is a cannabis-focused compliance and lending fintech trying to stabilize a shrinking core business while expanding services and preserving its Nasdaq listing. Its 2025 revenue fell nearly 50%, and management’s stated strategy has centered on rebuilding the core platform, broadening lending, and adding complementary businesses.
This is a strategic reset, not a normal partnership. SHF has signed a non-binding term sheet to combine with Opifex, a creator-economy media holding company, with Opifex becoming a wholly owned subsidiary. The proposed structure is expected to be accounted for as a reverse acquisition, meaning the economic control of the listed company would effectively shift to Opifex.
| Item | Proposed terms |
|---|---|
| Opifex holders’ ownership at closing | 85% fully diluted (Ownership) |
| Existing SHF stakeholders’ ownership | 15% fully diluted (Ownership) |
| Contemplated Opifex valuation | At least $50 million, subject to valuation and fairness opinion (Valuation) |
| Potential direct investment | Up to $1.0 million, subject to stockholder approval (Capital and Nasdaq Listing) |
| Target closing | Before April 19, 2027 (Timing and Conditions) |
The headline benefit is survival plus a new growth story. The deal is designed to bring a creator-economy platform into the public company, potentially supply capital, and help SHF meet Nasdaq’s listing requirements before its April 19, 2027 compliance deadline. But this is not an operating improvement in Safe Harbor’s cannabis fintech business; the release explicitly says that business is expected to continue without changing its client services. 〔0〕
Existing holders are giving up control for the rescue option. Opifex investors would own 85% of the combined company, while current SHF stakeholders would retain only 15% before any closing financing or equity-plan reserve. That makes this closer to a listed-shell recapitalization or reverse merger than an acquisition that materially benefits current SHF owners.
The dilution problem is already visible before the merger closes. SHF issued 23,914,988 common shares through Series B conversions during the July 1–October 23 issuance period, against 24,942,735 shares outstanding as of October 23. 〔1〕 The new merger structure also contemplates additional equity issuance, and all Series B securities would need to convert at closing, so the final ownership picture could be more dilutive than the headline 85%/15% split suggests.
Execution risk is unusually high because the key terms are unfinished. Opifex still must provide financial statements and audited results, the parties must negotiate definitive agreements, SHF needs stockholder and Nasdaq approval, Series B holders must consent, and financing may be required. The term sheet is non-binding apart from customary provisions, with only a 45-day exclusivity period. 〔2〕 There is no clean consensus benchmark for a transaction like this; relative to the pre-filing story, the surprise is the proposed pivot itself, while the cost is a major transfer of ownership and control.
Bottom line: The deal gives SHF a possible Nasdaq-preservation route and a new creator-economy platform, but it does so by handing Opifex effective control and leaving current holders with a minority stake. It materially changes the company’s identity, yet remains an unbinding, highly conditional plan rather than a completed turnaround.
Definitive agreement, audited Opifex financials, and stockholder vote
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!